Table 3.
Control group (n: 107) | Study group (n: 19) | P | |
---|---|---|---|
Caugh | 37% | 47% | 0.411 |
Dyspnea | 34% | 53% | 0.120 |
Chest pain | 5% | 11% | 0.310 |
Myalgia | 32% | 37% | 0.674 |
Nasal congestion | 5% | 6% | 0.918 |
Sore throat | 10% | 6% | 0.555 |
İnsomnia | 10% | 0% | 0.216 |
Headache | 6% | 16% | 0.116 |
Diarrhea | 3% | 0% | 0.458 |
Itching | 13% | 100% | < 0.001 |
Antenatal corticosteroid therapy | 18% | 37% | 0.061 |
Systemic steroid therapy | 30% | 32% | 0.837 |
Oxygen support | 37% | 53% | 0.193 |
Admission to ICU | 17% | 21% | 0.732 |
Admission to NICU | 8% | 15% | 0.313 |
Preterm delivery | 43% | 50% | 0.961 |
Maternal mortality | 7% | 15% | 0.237 |
A p-value of <0.05 was set to boldface